Alzheimer’s disease has been unresponsive to the biggest medical and scientific efforts, but a new treatment is in the works that may boost returns in neuroscience-related exchange traded funds (ETFs). The developments could also give hope of recovery for patients in the battle against the disease.
Denise Grady for The New York Times reports that scientists are now aware that Alzheimer’s may start at an earlier period in life, not in old age. It is thought to be a chronic condition that begins long before the mind fails. Changes may start as soon as mid-life and scientists are trying to pinpoint the disease before it progresses.
A radioactive dye called PIB (Pittsburgh Compound B) makes it possible to use a PET scan to find deposits of amyloid, an Alzheimer’s-related protein, in the brains of living human beings. It could lead to an earlier diagnosis, helping doctors distinguish between Alzheimer’s and other forms of dementia. PIB could also aid doctors in monitoring the effects of treatment.
Look into HealthShares Neuroscience (HHN) to find if PIB can trigger any returns.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.